Attached files

file filename
8-K - FORM 8-K - CELGENE CORP /DE/d366898d8k.htm

Exhibit 99.1

 

LOGO

 

Contact:    Jacqualyn A. Fouse    Patrick E. Flanigan III   
   Executive Vice President and    Vice President   
   Chief Financial Officer    Investor Relations   
   Celgene Corporation    Celgene Corporation   
   (908) 673-9956    (908) 673-9969   

CELGENE ANNOUNCES ADDITIONAL $2.5 BILLION

SHARE REPURCHASE PROGRAM

SUMMIT, NJ – (June 13, 2012) – Celgene Corporation (NASDAQ: CELG) today announced that during its June meeting the Company’s Board of Directors authorized the repurchase of up to an additional $2.5 billion of the Company’s common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene’s management and in accordance with the requirements of the Securities and Exchange Commission.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company’s Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

# # #